Newsletter 24/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Holidays are in the air, but we still have something new for you this week! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. […]
Cholesterol Identified as Key Shield in Heat-Resistant Cancer Cells
/in Hyperthermia, Preclinical Research/by MaxATRN-119: A New Promising ATR Inhibitor for ATM Mutations (And Other HRR Mutations)
/in Not PCa related/by MaxUPDATE: OncoACP3 Moving to Phase 1 Trial as Therapeutic Agent
/in Clinical Trial, Metastatic, Phase 1/by MaxSn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNewsletter 23/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! For biology discovery enthusiasts (and AI applications) like me, last week was really exciting! But we also have good news on the clinical trial front! Stay strong and fight on! As usual, we also have a podcast if you […]
Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Final PEACE-3 Trial Data: Radium-223 + Enzalutamide Extends Survival by 5.6 Months in Bone mCRPC. March 2, 2026
- Phase 2 Trial of Cu-64 SAR-bisPSMA Doubles Prostate Lesion Detection March 2, 2026
- Newsletter 9/2026 March 1, 2026
- CT Muscle Measure Guides Treatment Benefit in New Prostate Cancer: STAMPEDE Findings February 25, 2026